Business
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk: HBSS
GOSS 6-DAY DEADLINE ALERT: Gossamer Bio Investors With Losses May Seek to Lead the Class Action After Executives Allegedly Concealed Placebo Risk:
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"SAN FRANCISCO, May 26, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased or otherwise acquired Gossamer securities between June 16, 2025 and February 20, 2026.The lawsuit follows Gossamer's bombshell announcement on February 23, 2026 that top-line results for its Phase 3 PROSERA study did not meet the primary endpoint (the change from baseline in six-minute-walk distance at week 24). The study evaluated seralutinib for the treatment of pulmonary arterial hypertension (\"PAH\").The developments, including the trial failure and 80% stock drop, prompted national shareholder rights firm Hagens Berman to commence an investigation into the alleged pending claims that Gossamer violated federal securities laws. The firm encourages Gossamer investors who suffered substantial losses on Class Period GOSS investments to submit your losses now.The firm also encourages persons with knowledge who may be able to assist the investigation to contact its attorneys.View our latest video summary of the allegations: youtu.be/TOr_OsDdBXYClass Period: June 16, 2025 – Feb. 20, 2026Lead Plaintiff Deadline: June 1, 2026Visit: www.hbsslaw.com/investor-fraud/gossGossamer Bio, Inc. (GOSS) Securities Class Action:The litigation is focused on the propriety of Gossamer's disclosures about the Phase 3 PROSERA trial design, including its patient recruitment protocol and site-level monitoring.In the past, Gossamer has emphasized that serlutinib is a \"potential first-in-class therapeutic[,]\" which \"represents the possibility of a multi-billion-dollar opportunity across multiple indications[.]\"As recently as mid-November 2025, the company's management cited the highly successful Merck Phase 3 STELLAR study of sotatercept for treating PAH. Gossamer's management said, \"if you look at their data, the best performing region was Latin America, and we have actually more patients coming from those same geographies and same sites.\" Management also assured investors that \"we have gone to the places where precedent studies have shown the greatest amount of efficacy, as well as having an entry criteria that is ensuring that we have patients who, we believe, will really show an improvement based upon, again background disease at week 24.\"The...